In several neoplastic diseases including hepatocellular carcinoma (HCC) immunosuppression is correlated with disease stage, progression and outcome. Moreover, recent studies have demonstrated that cyclooxygenase-2 (COX-2) enhances tumor growth in HCCs. The present study analyzed the correlation between local immune responses and COX-2 gene expression levels in patients with primary HCCs.
Methods
Fresh tissues were obtained from 59 patients who underwent resection of an HCC. The COX-2 gene expression levels were quantified by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) and compared with the CD8+ T cell densities detected by immunohistochemistry.
Results
COX-2 gene expression was detected in 35 of the 59 tumors. The CD8+ T cell density in COX-2-expressing tumors (6.1 cells/high-power field (HPF), x200 magnification) was suppressed compared with that in non-COX-2-expressing tumors (13.6 cells/HPF, P = 0.009). Tumor COX-2 gene expression was associated with a poorer disease-free survival rate.
Conclusions
Elevation of the tumor COX-2 level is correlated with the suppression of local immune responses in HCCs, suggesting that COX-2 plays a role in early tumor recurrence in the residual liver in patients after HCC resection.
MiseK., TashiroS., YogitaS., WadaD., HaradaM., FukadaY., MiyakeH., IshikawaM., IzumiK., SanoN.: Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis.Clin Cancer Res,4: 1475–1482, 1998.
2.
RopponenK.M., EskelinenM.J., LipponenP.K., AlhavaE., KosmaV.M.: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.J Pathol,182: 318–324, 1997.
3.
IkeguchiM., SaitoH., KatanoK., TsujitaniS., MaetaM., KaibaraN.: Correlation between the lymphocytic infiltration of tumors and the proliferative activity of cancer cells from surgically treated esophageal carcinoma.Oncology,54: 311–317, 1997.
4.
IkeguchiM., OiK., HirookaY., KaibaraN.: CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma.Eur J Surg Oncol,30: 53–57, 2004.
5.
PockajB.A., BasuG.D., PathangeyL.B., GrayR.J., HernandezJ.L., GendlerS.J., MukherjeeP.: Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.Ann Surg Oncol,11: 328–339, 2004.
6.
Liver Cancer Study Group of Japan: Classification of primary liver cancer (First English Edition), pp 2–22, Kanehara Publishers, Tokyo, 1997.
7.
IkeguchiM., MatsumotoS., MurakamiD., KanajiS., OhroS., MaetaY., TatebeS., KondoA., TsujitaniS., KaibaraN.: Gene expression levels of cytokines in peritoneal washings from patients with gastric cancer.Tumor Biol,25: 117–121, 2004.
SmithW.L., GaravitoR.M., DeWittD.L.: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2.J Biol Chem,271: 33157–33160, 1996.
11.
SingerI.I., KawkaD.W., SchloemannS., TessnerT., RiehlT., StensonW.F.: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease.Gastroenterology,115: 297–306, 1998.
12.
ChengA.S., ChanH.L., ToK.F., LeungW.K., ChanK.K., LiewC.T., SungJ.J.: Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angio-genesis in hepatitis B virus-associated hepatocellular carcinoma.Int J Oncol,24: 853–860, 2004.
13.
TangT.C., PoonR.T., LauC.P., XieD., FanS.T.: Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma.World J Gastroenterol,11: 1896–1902, 2005.
14.
KernM.A., SchoneweissM.M., SahiD., BahloM., HauggA.M., KasperH.U., DienesH.P., KafersteinH., BreuhahnK., Shirma-cherP.: Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice.Carcinogenesis,25: 1193–1199, 2004.
15.
FoderaD., D'AlessandroN., CusimanoA., PomaP., Notarbar-toloM., LampiasiN., MontaltoG., CervelloM.: Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors.Ann NY Acad Sci, 1028: 440–449, 2004.
16.
KondoM., YamamotoH., NaganoH., OkamiJ., ItoY., ShimizuJ., EguchiH., MiyamotoA., DonoK., UmeshitaK., MatsuuraN., WakasaK., NakamoriS., SakonM., MondenM.: Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.Clin Cancer Res,5: 4005–4012, 1999.
17.
OhnoY., OhnoS., SuzukiN., KameiT., InagawaH., SomaG., InoueM.: Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma.Int J Cancer,114: 696–701, 2005.
18.
MunkarahA.R., MorrisR., BaumannP., DeppeG., MaloneJ., DiamondM.P., SaedG.M.: Effects of prostaglandin E2 on proliferation and apoptosis of epithelial ovarian cancer cells.J Soc Gynecol Investig,9: 68–173, 2002.
19.
HariziH., JuzanM., PitardV., MoreauJ.F., GualdeN.: Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions.J Immunol,168: 2255–2263, 2002.
20.
StolinaM., SharmaS., LinY., DohadwalaM., GardnerB., LuoJ., ZhuL., KronenbergM., MillerP.W., PortanovaJ., LeeJ.C., DubinettS.M.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis.J Immunol,164: 361–370, 2000.
21.
InoshimaN., NakanishiY., MinamiT., IzumiM., TakayamaK., YoshinoI., HaraN.: The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of nonsmall cell lung cancer.Clin Cancer Res,8: 3480–3486, 2002.
22.
TakahashiA., KonoK., ItakuraJ., AmemiyaH., Feng TangR., IizukaH., FujiiH., MatsumotoY.: Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer.Oncology,62: 121–127, 2002.
